Hepatocellular Carcinoma in the COVID‐19 Era: Primetime for Stereotactic Body Radiotherapy and a Lesson for the Future?

The COVID‐19 pandemic has presented an opportunity to evaluate current practices in cancer care. This letter to the editor focuses on one example, making the case for stereotactic body radiotherapy in Hepatocellular Carcinoma.

Detalles Bibliográficos
Autores principales: Scorsetti, Marta, Goodman, Karyn A., Seong, Jinsil, Loi, Mauro, Huguet, Florence, Dawson, Laura A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307056/
https://www.ncbi.nlm.nih.gov/pubmed/32525607
http://dx.doi.org/10.1634/theoncologist.2020-0416
Descripción
Sumario:The COVID‐19 pandemic has presented an opportunity to evaluate current practices in cancer care. This letter to the editor focuses on one example, making the case for stereotactic body radiotherapy in Hepatocellular Carcinoma.

Ejemplares similares